Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 245,697 shares, an increase of 227.7% from the November 30th total of 74,987 shares. Approximately 7.1% of the shares of the stock are short sold. Based on an average daily volume of 566,481 shares, the short-interest ratio is presently 0.4 days. Based on an average daily volume of 566,481 shares, the short-interest ratio is presently 0.4 days. Approximately 7.1% of the shares of the stock are short sold.

Jaguar Animal Health Trading Up 2.2%

Shares of NASDAQ:JAGX opened at $1.11 on Friday. Jaguar Animal Health has a 1 year low of $1.00 and a 1 year high of $33.25. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.81 and a quick ratio of 0.52. The firm has a market capitalization of $4.17 million, a P/E ratio of -0.03 and a beta of -0.12. The business’s 50-day moving average is $1.51 and its 200 day moving average is $2.03.

Jaguar Animal Health (NASDAQ:JAGX) last posted its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($6.28) EPS for the quarter, missing the consensus estimate of ($5.08) by ($1.20). The company had revenue of $3.08 million for the quarter, compared to analyst estimates of $3.73 million. Jaguar Animal Health had a negative return on equity of 1,194.94% and a negative net margin of 341.90%. On average, research analysts predict that Jaguar Animal Health will post -0.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Jaguar Animal Health presently has an average rating of “Hold” and a consensus price target of $60.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.